Related Experiment Video
Updated: Jun 10, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Fyn-tau-amyloid: a toxic triad
Christian Haass1, Eckhard Mandelkow
1German Center for Neurodegenerative Diseases, 80336 Munich, Germany. chaass@med.uni-muenchen.de
Cell
|August 10, 2010
Summary
The study reveals a new role for the tau protein in neuronal dendrites, explaining its involvement in Alzheimer's disease pathogenesis and how amyloid beta-peptide toxicity is mediated.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathogenesis of Alzheimer's Disease
Background:
- Alzheimer's disease pathogenesis involves tau protein and amyloid beta-peptide (Abeta).
- The mechanism by which tau mediates Abeta toxicity is not fully understood.
Discussion:
- Ittner et al. (2010) identified a novel physiological function for tau within neuronal dendrites.
- This discovery offers a potential explanation for tau's role in mediating Abeta toxicity.
Key Insights:
- Tau protein has an unexpected function in neuronal dendrites.
- This dendritic tau function may be the key to understanding Abeta-mediated neurotoxicity in Alzheimer's disease.
Outlook:
- Further research into tau's dendritic function could reveal new therapeutic targets.
- Understanding this mechanism could lead to novel strategies for combating Alzheimer's disease progression.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...